Mitotech Announces Phase 2 Data Showing Positive Effect of SkQ1 in Patients with Dry Eye Syndrome
SkQ1 is the first mitochondria-targeted antioxidant to reach clinical phase of development for an ophthalmic indication
RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S.
U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc.
Fields Medal winner Manjul Bhargava to give 2015 Commencement address, joining honorand Mark Abelson
Bates News
Two Decades In Translation
For 20 years, “Therapeutic Topics” has explored ocular disease. Here’s an update on where translational medicine stands today.
Herantis Pharma has initiated Phase 2 study with Cis-UCA Eye Drops
Dry Eye Syndrome, results expected in Q3/2015
Ora-CAC®Model Provided Platform for Recent Positive Phase 2 Data for Ocular Therapeutix's OTX-DP in Allergic Conjunctivitis
A drug-eluting punctum plug being evaluated by Ocular Therapeutix
Nicox's shareholders approve acquisition of Aciex Therapeutics, Inc.
The acquisition of Aciex represents a significant step forward in Nicox’s strategy of creating an international ophthalmic company
RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy
Continuing to show positive results in Phase 3 will be an important breakthrough for treating NK
Thoughts on Healing the Wounded Cornea
A look at the mechanism behind neurotrophic keratitis as well as current and future methods for treating it.